A
Andrea Corbacioglu
Researcher at University of Ulm
Publications - 42
Citations - 5039
Andrea Corbacioglu is an academic researcher from University of Ulm. The author has contributed to research in topics: Myeloid leukemia & Gene mutation. The author has an hindex of 18, co-authored 41 publications receiving 4582 citations. Previous affiliations of Andrea Corbacioglu include Brigham and Women's Hospital.
Papers
More filters
Journal ArticleDOI
Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia
Richard F. Schlenk,Konstanze Döhner,Jürgen Krauter,Stefan Fröhling,Andrea Corbacioglu,Lars Bullinger,Marianne Habdank,Daniela Späth,Michael Morgan,Axel Benner,Brigitte Schlegelberger,Gerhard Heil,Arnold Ganser,Hartmut Döhner +13 more
TL;DR: Genotypes defined by the mutational status of NPM1, FLT3, CEBPA, MLL, and MLL are associated with the outcome of treatment for patients with cytogenetically normal AML.
Journal ArticleDOI
Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations.
Konstanze Döhner,Richard F. Schlenk,Marianne Habdank,Claudia Scholl,F.G. Rücker,Andrea Corbacioglu,Lars Bullinger,Stefan Fröhling,Hartmut Döhner +8 more
TL;DR: NPM1 mutations in the absence of FLT3 ITD define a distinct molecular and prognostic subclass of young-adult AML patients with normal cytogenetics, and is associated with specific clinical, phenotypical, and genetic features.
Journal ArticleDOI
RUNX1 Mutations in Acute Myeloid Leukemia: Results From a Comprehensive Genetic and Clinical Analysis From the AML Study Group
Verena I. Gaidzik,Lars Bullinger,Richard F. Schlenk,Andreas Zimmermann,Jürgen Röck,Peter Paschka,Andrea Corbacioglu,Jürgen Krauter,Brigitte Schlegelberger,Arnold Ganser,Daniela Späth,Andrea Kündgen,Ingo G.H. Schmidt-Wolf,Katharina Götze,David Nachbaur,Michael Pfreundschuh,Heinz A. Horst,Hartmut Döhner,Konstanze Döhner +18 more
TL;DR: AML with RUNX1 mutations are characterized by distinct genetic properties and are associated with resistance to therapy and inferior outcome, and Explorative subgroup analysis revealed that allogeneic hematopoietic stem-cell transplantation had a favorable impact on RFS in RunX1-mutated patients.
Journal ArticleDOI
Monitoring of Minimal Residual Disease in NPM1-Mutated Acute Myeloid Leukemia: A Study From the German-Austrian Acute Myeloid Leukemia Study Group
Jan Krönke,Richard F. Schlenk,Kai-Ole Jensen,Florian Tschürtz,Andrea Corbacioglu,Verena I. Gaidzik,Peter Paschka,Shiva Onken,Karina Eiwen,Marianne Habdank,Daniela Späth,Michael Lübbert,Mohammed Wattad,Thomas Kindler,Helmut R. Salih,Gerhard Held,David Nachbaur,Marie von Lilienfeld-Toal,Ulrich Germing,Detlef Haase,Hans-Günther Mergenthaler,Jürgen Krauter,Arnold Ganser,Gudrun Göhring,Brigitte Schlegelberger,Hartmut Döhner,Konstanze Döhner +26 more
TL;DR: Clinically relevant time points for NPM1(mut) MRD assessment are defined that allow for the identification of patients with AML who are at high risk of relapse.
Journal ArticleDOI
Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity
Erdogan Taskesen,Lars Bullinger,Andrea Corbacioglu,Mathijs A. Sanders,Claudia Erpelinck,Bas J. Wouters,Sonja C P A M van der Poel-van de Luytgaarde,Frederik Damm,Jürgen Krauter,Arnold Ganser,Richard F. Schlenk,Bob Löwenberg,Ruud Delwel,Hartmut Döhner,Peter J. M. Valk,Konstanze Döhner +15 more
TL;DR: It is proposed that CEBPA(dm) should be clearly defined from CEbPA(sm) AML and considered as a separate entity in the classification of AML.